Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: Need we be afraid?

Transfusion

Volumn 55, Issue 2, 2015, Pages 430-439

  Bonig, Halvard ^a   Becker, Petra S ^b   Schwebig, Arnd ^c   Turner, Matthew ^d  

^a GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^b Institute of Transfusion Medicine   (Germany)

^c Sandoz Biopharmaceuticals   (Germany)

^d Sandoz Pharma Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; FILGRASTIM; GRANULOCYTE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY;

ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CLINICAL PRACTICE; DRUG APPROVAL; DRUG SAFETY; EPIGENETICS; GENETIC DAMAGE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOGENICITY; LEUKOCYTE DISORDER; LYMPHOCYTE FUNCTION; NONHUMAN; REVIEW; STEM CELL MOBILIZATION; UNSPECIFIED SIDE EFFECT; FOOD AND DRUG ADMINISTRATION; LIVING DONOR; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROCEDURES; UNITED STATES;

ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LIVING DONORS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84923020739     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12770     Document Type: Review

References (69)

1. European Medicines Agency. Scientific guidelines on biosimilar medicines. EMA, London, 2005-2013 [cited 2013 Nov 6]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general-content-000408.jsp&mid=WC0b01ac058002958c
2. Food and Drug Administration (FDA). Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), February 2012 [cited 2014 Mar 5]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128
3. Australian Therapeutic Goods Administration (TGA). Evaluation of biosimilars. Version 1.0, July 2013 [cited 2014 May 19]. Available from: http://www.tga.gov.au/pdf/pm-argpm-biosimilars.pdf
4. Roger SD, Goldsmith D,. Biosimilars: it's not as simple as cost alone. J Clin Pharm Ther 2008; 33: 459-464.
5. Kidney Disease Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2: 279-335.
6. Schellekens H,. Biosimilar therapeutics-what do we need to consider? NDT Plus 2009; 2 (Suppl 1): i27-36.
7. Weise M, Bielsky MC, DeSmet K, et al. Biosimilars: what clinicians should know. Blood 2012; 120: 5111-5117.
8. Miller JP, Perry EH, Price TH, et al. Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. Biol Blood Marrow Transplant 2008; 14: 29-36.
9. Anderlini P,. Effects and safety of granulocyte colony-stimulating factor in healthy volunteers. Curr Opin Hematol 2009; 16: 35-40.
10. Pulsipher MA, Chitphakdithai P, Miller JP, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009; 113: 3604-3611.
11. Nuama NM, Goker H, Kilic YA, et al. Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature. Haematologica 2006; 91: e26-28.
12. Miura Y, Kami M, Yamada M, et al. Rapid diffuse alveolar hemorrhage associated with all-trans-retinoic acid and filgrastim. Am J Hematol 2008; 83: 683.
13. Ganetsky A, Kucharczuk C, Del Percio S, et al. Spontaneous subcapsular splenic hematoma associated with filgrastim in a patient undergoing allogeneic hematopoietic stem cell transplantation. Ann Pharmacother 2013; 47: e22.
14. Nagler A, Korenstein-Ilan A, Amiel A, et al. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004; 32: 122-130.
15. Bennett CL, Evens AM, Andritsos LA, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135: 642-650.
16. Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010; 28: 2914-2924.
17. Marmier-Savet C, Larosa F, Legrand F, et al. Persistence of lymphocyte function perturbations after granulocyte-colony-stimulating factor mobilization and cytapheresis in normal peripheral blood stem cell donors. Transfusion 2010; 50: 2676-2685.
18. Vokurka S, Koza V, Jungova A, et al. Haematological malignancies in sibling and unrelated donors of allogeneic peripheral stem cells mobilised with G-CSF filgrastim: a transplant centre and Czech National Marrow Donors Registry experience. Bone Marrow Transplant 2012; 47: 867-868.
19. Hölig K, Kramer M, Kroschinsky F, et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009; 114: 3757-3763.
20. Müller MM, Bialleck H, Bomke B, et al. Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G-CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5-year follow-up study. Vox Sang 2013; 104: 46-54.
21. European Group for Blood and Marrow Transplantation (EBMT). Position statement: biosimilar granulocyte-colony stimulating factor (G-CSF) for stem cell mobilization in related and unrelated donors. 2009 [cited 2014 Feb 27]. Available from: http://www.worldmarrow.org/fileadmin/Committees/CLWG/Biosimilars/Biosimilars-9Jan09.pdf
22. Shaw BE, Confer DL, Hwang WY, et al. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica 2011; 96: 942-947.
23. Gastl G, Geissler D, Geissler K, et al. Austrian Society of Hematology and Oncology position on biosimilars. Mag Eur Med Oncol 2009; 4: 232-233.
24. Barosi G, Bosi A, Abbracchio MP, et al. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica 2011; 96: 937-942.
25. Japan Society for Hematopoietic Cell Transplantation. Position statement of the Japan Society for Hematopoietic Cell Transplantation regarding the use of biosimilar granulocyte-colony stimulating factors for the mobilization of hematopoietic stem cells in healthy donors. April 2013 [cited 2014 Feb 18]. Available from: http://www.jshct.com/english
26. Gascõn P, Fuhr U, Sörgel F, et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol 2010; 21: 1419-1429.
27. Lubenau H, Sveikata A, Gumbrevicius G, et al. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharmacol Ther 2009; 47: 275-282.
28. Lubenau H, Bias P, Maly AK, et al. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 2009; 23: 43-51.
29. del Giglio A, Eniu A, Ganea-Motan D, et al. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 2008; 8: 332.
30. Engert A, del Giglio A, Bias P, et al. Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma. Onkologie 2009; 32: 599-604.
31. Gatzemeier U, Ciuleanu T, Dediu M, et al. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 2009; 4: 736-740.
32. ®) for febrile and chemotherapy-induced neutropenia. Biosimilars 2012; 2: 1-11.
33. Schiestl M, Stangler T, Torella C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29: 310-312.
34. Lefrère F, Brignier AC, Elie C, et al. First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor. Adv Ther 2011; 28: 304-310.
35. Manko J, Walter-Croneck A, Jawniak D, et al. A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization. Pharmacol Rep 2014; 66: 239-242.
36. Czerw T, Kruzel T, Sadus-Wojciechowska M, et al. Comparison of two formulations of filgrastim, Neupogen (Amgen) and Zarzio (Sandoz), used to accelerate neutrophil recovery after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2012; 47 (Suppl 1): S316 (P872).
37. Ianotto JC, Tempescul A, Yan X, et al. Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients. Bone Marrow Transplant 2012; 47: 874-876.
38. Kotwica K, Cioch M, Wach M, et al. Biosimilar G-CSF is effective in reducing the duration of neutropenia after autologous bone marrow transplantation. Bone Marrow Transplant 2012; 47 (Suppl 1): S316 (P873).
39. ®, Sandoz, granulocyte colony-stimulating factor). Bone Marrow Transplant 2013; 48 (Suppl 2): S114 (P519).
40. th Annual Meeting of the American Society of Haematology (ASH), New Orleans, LA, USA, December 7-10, 2013.
41. Ostuni A, Morciano MR, Mele A, et al. Zarzio plus chemotherapy as peripheral blood stem cell mobilization strategy in patients with haematological diseases candidated to autologous stem cell transplantation. Bone Marrow Transplant 2013; 48 (Suppl 2): S120 (P529).
42. Publicover A, Richardson DS, Davies A, et al. Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment. Br J Haematol 2013; 162: 107-111.
43. th Annual Meeting of the American Society of Haematology (ASH), New Orleans, LA, USA, December 7-10, 2013.
44. Yafour N, Brahimi M, Osmani S, et al. Biosimilar G-CSF (filgrastim) is effective for peripheral blood stem cell mobilization and non-cryopreserved autologous transplantation. Transfus Clin Biol 2013; 20: 502-504.
45. ®) for haematopoietic progenitor cell mobilization in patients with haematological malignancies. Bone Marrow Transplant 2013; 48 (Suppl 2): S112 (P515).
46. Azar N, Choquet S, Garnier A, et al. Use of a biosimilar G-CSF in allogeneic stem cell mobilisation. Bone Marrow Transplant 2012; 47 (Suppl 1): S316 (P727).
47. ®) for haematopoietic progenitor cell mobilization in allogeneic healthy donors. Bone Marrow Transplant 2013; 48 (Suppl 2): S102 (P491).
48. Schmitt M, Xu X, Hilgendorf I, et al. Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors. Bone Marrow Transplant 2013; 48: 922-925.
49. Becker P, Brauninger S, Bialleck H, et al. Biosimilar filgrastim mobilizes haematopoietic stem cells in healthy volunteer donors with expected efficiency and typical acute adverse effects: interim results of a post-authorization safety study. Bone Marrow Transplant 2013; 48 (Suppl 2): S28 (O177).
50. McCamish M, Woollett G,. The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary? Clin Pharmacol Ther 2013; 93: 315-317.
51. Abraham I, Tharmarajah S, MacDonald K,. Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. Expert Opin Drug Saf 2013; 12: 235-246.
52. World Marrow Donor Association (WMDA). Donor medical suitability recommendations. 2013 [cited 2014 May 19]. Available from: http://www.worldmarrow.org/donorsuitability/index.php/Main-Page
53. Foundation for the Accreditation of Cellular Therapy/Joint Accreditation Committee-ISCT & EBMT (FACT/JACIE). Cellular therapy standards. 2013 [cited 2014 May 19]. Available from: http://www.factwebsite.org/ctstandards/
54. Hölig K,. G-CSF in healthy allogeneic stem cell donors. Transfus Med Hemother 2013; 40: 225-235.
55. Pulsipher MA, Chitphakdithai P, Logan BR, et al. Lower risk of serious adverse events and no increased risk of cancer after PBSC versus bone marrow donation. Blood 2014; 123: 3655-3663.
56. Schellekens H,. When biotech proteins go off-patent. Trends Biotechnol 2004; 22: 406-410.
57. Pollock C, Johnson DW, Hörl WH, et al. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2008; 3: 193-199.
58. Tigue CC, McKoy AM, Evens AM, et al. Granulocyte colony-stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview on safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007; 40: 185-192.
59. Falanga A, Marchetti M, Evangelista V, et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 1999; 93: 2506-2514.
60. LeBlanc R, Roy J, Demers C, et al. A prospective study of G-CSF effects on hemostasis on allogeneic blood stem cell donors. Bone Marrow Transplant 1999; 23: 991-996.
61. Bonig H, Burdach S, Göbel U, et al. Growth factors and hemostasis: differential effects of GM-CSF and G-CSF on coagulation activation-laboratory and clinical evidence. Ann Hematol 2001; 80: 525-530.
62. Topcuoglu P, Arat M, Dalva K, et al. Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors. Bone Marrow Transplant 2004; 33: 171-176.
63. Báez A, Martín-Antonio B, Piruat JI, et al. The granulocyte colony-stimulating factor produces long-term changes on gene and miRNA expression profiles in CD34+ cells from healthy donors. Haematologica 2014; 99: 243-251.
64. Winkler IG, Bendall LJ, Forristal CE, et al. B-lymphopoiesis is stopped by mobilizing doses of G-CSF and is rescued by overexpression of the anti-apoptotic protein Bcl2. Haematologica 2013; 98: 325-333.
65. Hirsch B, Oseth L, Cain M, et al. Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors. Blood 2011; 118: 2602-2608.
66. Schuettpelz LG, Link DC,. Regulation of hematopoietic stem cell activity by inflammation. Front Immunol 2013; 4: 204.
67. Gascõn P, Tesch H, Verpoort K, et al. Clinical experience with Zarzio® in Europe: what have we learned? Support Care Cancer 2013; 21: 2925-2932.
68. Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81: 1883-1888.
69. Bensinger WI, Buckner CD, Rowley S, et al. Treatment of normal donors with recombinant growth factors for transplantation of allogeneic blood stem cells. Bone Marrow Transplant 1996; 17 (Suppl 2): S19-21.